With its first clinical study underway, Acousia is taking significant strides towards achieving its goal of developing novel medicines that enhance and preserve natural hearing for patients with SNHL.

Acousia develops small molecule drug candidates as a first-line treatment for patients in need of immediate, high, and localized drug exposure to help preserve their hearing. Following the CTA (Clinical Trial Authorization) from the German BfArM (Federal Institute for Drugs and Medical Devices), Acousia has commenced its first clinical study of ACOU085 in patients with age-related hearing loss. Furthermore, the next generation of drug candidates are already in the early stages of development.

Our therapy approach is a dual mode of action that is suitable for both acute and chronic hearing loss and strives to both enhance and preserve a patient’s natural hearing ability. The different chemical makeups of our small drug molecules, as well as their modes of administration, are specifically designed to target acute, permanent, and progressive sensorineural hearing loss.